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(P  0.05). In addition, patients’ race and gender do not affect the medication adher-
ence (P  0.10) and, patients’ years of education, BMI and age are positively associated 
with adherence (P  0.05). CONCLUSIONS: In recent years, one out of three people 
in U.S. had at least one gap in insurance coverage due to job change or temporary 
unemployment in the United States. Studies focusing on the current insurance status 
may underestimate the impact of health insurance gaps and the population at risk.
The policy debates on health insurance should not only focus on the uninsured but
also those affected by intermittent non-coverage. Further research is needed on 
how insurance instability may affect treatment of other chronic conditions other than
hypertension.
CM2
UTILIZATION AND PERSISTENCE OF ALISKIREN IN A REAL-WORLD
ENVIRONMENT
Zeng F1, Lau H2, Hanson K2, Patel BV1, Gao S1
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA
OBJECTIVES: Aliskiren is the ﬁ rst marketed direct renin inhibitor approved for
the treatment of hypertension in 2007. Study objectives were to evaluate the utilization 
and persistence of aliskiren in a real-world setting. METHODS: A retrospective cohort 
analysis was conducted using data from a large US pharmacy beneﬁ t manager who 
administers beneﬁ ts to 27 million members nationally. Patients 18 years or older
with at least two claims for aliskiren within a 12 month period of initiating treat-
ment between April 2007 and October 2007 were included in the analysis. Patients
also were required to be continuously enrolled in the same health plan 12 months 
prior to and 13 months after initiating aliskiren. Persistence on aliskiren, deﬁ ned 
as time to discontinuation (i.e., 30 day medication gap), was evaluated using a 
multivariate Cox proportional hazards model. Co-variates adjusted in the model
included age, sex, comorbidities, geographical region, insurance type, copay, pre-
scriber specialty and prior antihypertensive utilization. RESULTS: A total of 1329 
patients were identiﬁ ed as having received aliskiren. Mean patient age was 63.5 (s.d. 
 13) years and 52.3% were female. Most patients receiving aliskiren were not
naïve to antihypertensive treatment. In the 12 months prior to initiating aliskiren, 
90.1% of patients had received at least one other antihypertensive medication, and
57.3% had used 3 or more classes of antihypertensives. Mean persistence on 
aliskiren was 248 (s.d.  132) days. Multivariate analysis of persistence on aliskiren 
suggest that the risk of discontinuing was higher among those with copays q$50 
relative to copays between $0 and $5 (Hazard ratio:1.74, 95% CI: 1.34–2.34).
CONCLUSIONS: Aliskiren is most used among patients previously treated with other
antihypertensives and a lower pharmacy copay was an important factor associated 
with medication persistence. Additional research is needed to assess clinical implica-
tions of persistence.
CM3
THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS’
COMPLIANCE WITH STATINS
Zhang D, Henderson SC, Denarie MF
IMS Health, Blue Bell, PA, USA
OBJECTIVES: To investigate the impact of Medicare Part D on elderly patients’
compliance with statins. METHODS: This is a quasi-experimental study with a
pre-test and post-test for a treatment and comparison group. This study used IMS 
Health’s LifeLink longitudinal patient level data. The subjects were elderly patients 
who ﬁ lled prescriptions for statins in both January 2005 and January 2006. The sub-
jects who enrolled in Medicare Part D in 2006 served as the treatment group and 
those who did not enroll served as the comparison group. Compliance was measured
by proportion of days covered (PDC) over 11 months in both 2005 (pre-test) and
2006 (post-test). The subjects’ baseline characteristics including age, gender, payment
type, and patient type (statin naive vs. continuing) were compared by t-test or chi-
square test. The difference-in-difference model was used to test whether Medicare
Part D has an impact on patients’ compliance. RESULTS: A total of 473,475 elderly
patients ﬁ lled statin prescriptions in both January 2005 and January 2006. The mean 
age was 71.6 years with 55.85% female. A majority of the subjects was continuing
statin users in 2005 (97.52%) and had pharmacy insurance (97.98%). A total of 
201,378 (42.53%) patients enrolled in Medicare Part D in 2006. Female patients
(chi-square  6101.43, p  0.0001) and patients who paid their prescriptions by cash
in 2005 (chi-square  2264.82, p  0.0001) were more likely to enroll Medicare Part
D in 2006. The average PDC was 80.33% and 74.40% for Medicare Part D patients
and 80.04% and 71.80% for non-Medicare Part D patients in 2005 and 2006,
respectively. After controlling baseline characteristics, Medicare Part D patients had
2.31% more PDC than non-Medicare Part D patients (b  2.31, t  23.69, p  0.0001). 
CONCLUSIONS: Medicare Part D has a signiﬁ cant and positive impact on elderly
patients’ medication compliance. It is important to encourage elderly patients to enroll
Medicare Part D.
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NONADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR MULTIPLE
DISEASE CONDITIONS IN A CALIFORNIA MEDICAID POPULATION
Nichol MB1, Knight TK1, Priest JL2, Wu J1, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle
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OBJECTIVES: To assess quality of care in selected California Medicaid(Medi-Cal)
diseases through evaluation of adherence to clinical practice guidelines(CPG) and
medications. METHODS: Eligibility and claims data (2002–2004) were used to 
identify patients with hyperlipidemia(HYPL), hypertension(HYPT), coronary artery 
disease(CAD), congestive heart failure(CHF), diabetes(DIAB), or depression(DEP). 
Adherence was assessed using 2004 data. CPG adherence was based on appropriate 
medication use and adherence to recommended laboratory tests(HbA1c,LDL-C) and 
eye examinations for diabetes patients. Nonadherence to medications was based on 
medication possession ratio 0.8. Chi-square tests were conducted to evaluate the 
association of CPG and medication nonadherence with demographic variables. 
RESULTS: The proportion of patients not using appropriate medications varied by 
disease(62% DEP, 43% HYPT, 40% HYPL, 31% CAD, 25% for both DIAB and 
CHF). Approximately 74% of CHF patients were not using any beta blocker(BB).
Younger age (65 years;p  0.01), Blacks(vs. Whites;p  0.0001), and Medicaid-only 
patients(vs. Medicare/Medicaid dually eligible;p  0.0001,non signiﬁ cant for BB) were 
more likely to lack appropriate medications, with the exception of depression, where
older patients and whites were more likely without appropriate medications(all p 
0.0001). For diabetes patients, 90% lacked HbA1c test, 84% lacked LDL-C test, and
57% were without an eye exam. Older and dually eligible patients were less adherent
with these measures (all p  0.0001). Nonadherence with medications was high (84%
DEP, 72% CHF, 69% HYPT, 51% CAD, 48% HYPL, 41% DIAB), with younger 
age(p  0.05), Blacks(p  0.0001), and Medicaid-only patients(p  0.0001, non sig-
niﬁ cant for BB) more likely nonadherent than comparison subgroups. CONCLU-
SIONS: Medi-Cal adherence to CPG and medications varied by condition, but was 
suboptimal across all diseases. A greater proportion of patients were nonadherent to 
medication than were not using appropriate medications. Future investigation focused
on potential factors inﬂ uencing medication nonadherence(i.e.,poor disease knowledge, 
cultural beliefs) is recommended. Disease-management programs designed for speciﬁ c 
diseases, and addressing patient-related characteristics (age, race) along with alterable
factors(eligibility), may be most effective for improving adherence.
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PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 
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OBJECTIVES: Type 2 diabetes is a chronic illness that affects more than 17 million 
Americans, leading to early death as well as to reduced quality of life due to com-
plications such as blindness, renal failure etc. This study was undertaken with the
aim of estimating cost-effectiveness of the premix analog insulin, biphasic insulin
aspart 30 (BIAsp), when switched from biphasic human insulin (BHI). METHODS:
The well validated CORE Diabetes Model was used to project the clinical outcomes 
based on short-term data (26 weeks) from a Canadian subset of the IMPROVE™ 
observational study. The cohort (n  310) had a mean age of 64.2 o 10.96 years 
and 61.7% are male. In the IMRPOVE™ study, patients were switched from BHI 
to BIAsp and the main results included a reduction of HbA1c from 8.42 o 1.61% 
to 7.84 o 1.46%, an increase in BMI of 0.28 o 2.33 kg/m2 and a reduction in major
and minor hypoglycemic events by 75% and 33%, respectively. Total direct medical
costs (complications  treatment costs) were projected, using US unit costs, over
patient lifetimes, and future costs and clinical beneﬁ ts discounted at 3% per annum. 
RESULTS: The short-term beneﬁ ts of switching from BHI to BIasp are projected to
lead to an increase in discounted quality-adjusted life expectancy of 0.276 years (4.289
o 0.094 versus 4.013 o 0.098). Increased total lifetime costs/patient is $4,936 ($84,776
o 2,423 versus $79,840 o 2,545) with BIasp. Combining costs and clinical outcomes 
result in an incremental cost-effectiveness ratio of $17,859 per quality-adjusted life 
year (QALYs) gained. CONCLUSIONS: Higher acquisition costs of BIasp are pro-
jected to be partly offset by reduced later diabetes-related complications. The net life 
time cost increase is greatly justiﬁ ed by improved outcomes. The incremental cost-
effectiveness ratio is well within what is normally considered good value for money 
in the United States.
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ANTI-HYPERTENSIVE DRUG USE AND RISK OF DEMENTIA IN
PATIENTS WITH DIABETES MELLITUS (DM)
Johnson ML1, Parikh NM2, Kunik M3, Schulz P4, Chen H1, Aparasu R1, Yadav R1, Morgan R5
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OBJECTIVES: Anti-hypertensive therapy (AHT), especially the drug classes acting on 
Renin-Angiotensin system (RAS) and Calcium Channel Blockers (CCB), is known to 
delay the onset of dementia. The aim of this study was to determine whether different 
AHT drug classes are independent risk factors for dementia in DM patients, who are
at increased risk of dementia. METHODS: For the purpose of this retrospective study, 
we identiﬁ ed a national cohort of US veterans (age q 65 years) with incident DM
between October 1996 and December, 2000 in the VA records or between January,
1999 and December, 2000 in the VA-Medicare merged data. The presence of hyperten-
sion (HT) was also assessed within the same period. The period prevalence for each 
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anti-hypertensive drug class was assessed in the calendar year (CY) 2000. The time 
to the incidence of dementia was assessed from CY2001 to CY2002. A Multivariable 
Cox regression model adjusted for sociodemographic factors, comorbidities, comedi-
cations and other factors was constructed to estimate the adjusted relative risk of 
dementia associated with use of AHT drug classes. The analysis was stratiﬁ ed for 
patients with and without hypertension. RESULTS: A total 377,838 patients were 
included in the ﬁ nal analysis. The adjusted Hazard Ratios [HRs, (95% CI)] for risk
of dementia with different classes was: Angiotensin receptor blockers (ARB) 0.76
(0.70–0.83), Angiotensin converting enzyme inhibitors (ACEI) 0.89 (0.85–0.93), CCB 
0.93 (0.89–0.97), Diuretics 0.86 (0.83–0.90), Alpha blockers 1.05(1.00–1.09) and 
Beta-Blockers 0.96 (0.92”C1.00). Only ACEI and ARB were signiﬁ cant in a stratiﬁ ed
analysis of patients with HT (ACEI 0.89, 0.85–0.93; ARB 0.78, 0.71–0.85) and 
patients without HT (ACEI 0.81, 0.69–0.94; ARB 0.55 (0.34–0.88). CONCLU-
SIONS: Drugs acting on the Renin-Angiotensin system (RAS) may be protective for 
dementia irrespective of the status of hypertension. More studies are required to
explore this association further.
DB3
DIRECT AND INDIRECT COSTS ASSOCIATED WITH DIABETES
PATIENTS WITH AND WITHOUT MACROVASCULAR COMORBIDITIES
IN THE UNITED STATES
Qiu Y1, Fu AZ2, Radican L1
1Merck & Co., Inc, Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Macrovascular disease remains a common and costly comorbidity
in patients with diabetes. The purpose of this study was to examine the marginal 
impact of macrovascular comorbidities on direct and indirect costs associated with 
patients with diabetes in the United States. METHODS: Using the pooled Medical
Expenditure Panel Survey (MEPS) 2003 and 2005 data, a nationally representative 
adult sample (age   18) was included in the study. Direct cost was measured by 
the total health care expenditure. Indirect cost was calculated from the lost produ-
ctivity from missed work days and additional bed days due to illness/injury based on
the 2005 average national hourly wage. The direct costs of both 2003 and 2005 data 
were adjusted to 2005 dollars. Given the heavily right-skewed distribution of the cost 
data, GLM with log-link function and gamma variance was used to identify the rela-
tionship between macrovascular conditions and costs after controlling for age, sex, 
race, ethnicity, education, income, smoking status, health insurance, and number of 
other comorbid categories. Negative binomial models were applied to analyze the 
outcomes of missed work days and bed days. All statistics were adjusted using the
proper sampling weight from the MEPS. RESULTS: The average annual health care
expense for patients with diabetes was $10,909. The average annual missed work days
and additional bed days due to illness/injury for patients with diabetes were 6.3 and 
14.8, respectively, equivalent to $2366 in total. Compared to diabetes patients without 
macrovascular comorbidities (N  3132), those with macrovascular comorbidities
(N  762) had statistically signiﬁ cant higher annual health care expenses ($3587,
p  0.001), more missed work days (4.05, p  0.01) and more bed days (7.15,
p  0.001). The marginal lost productivity cost was $1257 annually. CONCLUSIONS:
Macrovascular comorbidities in patients with diabetes result in increased direct and
indirect costs.
DB4
COST OF DIABETIC-RELATED COMPLICATIONS AND
CARDIOVASCULAR EVENTS BY TYPE OF EVENT AND SETTING
ANNUALLY FOR THE FIRST THREE YEARS FOLLOWING ITS ONSET
Simons WR1, Hagan MA2
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Daiichi-Sankyo, 
Wayne, NJ, USA
OBJECTIVES: This study evaluates using Tobit regressions the costs speciﬁ c to each 
type of complication following its onset in annual increments for three years by setting 
(inpatient and outpatient). METHODS: We use a U.S. managed care database to 
identify newly diagnosed type 2 diabetics and then identify the initial onset of 
manifestations of diabetic related complications. Detailed ICD-9 codes associated 
with each type of complication were used to deﬁ ne dichotomous variables as well as 
a time to event variable, one for each selected type of complication. Outpatient and 
inpatients costs were accrued for one, two and three year periods. Because of the
number of zero costs (i.e., not everyone consumes resources such as hospitalization
annually), Tobit regressions were used, a combination of a probit probability model
and a linear regression to resolve the disproportionality in resource utilization. Param-
eter estimates from a Tobit are not directly interpretable as those from a linear regres-
sion and require transformation to obtain the predicted cost values. RESULTS: A total
of 351,900 type 2 diabetics were used in the analyses; 663 patients consumed inpatient
services compared to 226,972 patients consuming outpatient services in year one 
related to a manifestation of a diabetic related complication. For those who encoun-
tered inpatient services, ischemic heart disease ($43,269), congestive heart failure 
($43,870), ketoacidosis ($29,588) and renal manifestations ($24,995) were the most
costly. Outpatient costs for these complications were signiﬁ cantly less, $682, $781, 
$1,031, and $1,267, respectively. Following the onset of these complications addi-
tional costs continued to accrue in year 2, $50,158, $51,669, $35,080 and $28,823,
albeit at a declining rate. The total ﬁ rst year cost across all types of complications was 
$2,827 per person (a 0.00993 ﬁ rst year event rate). CONCLUSIONS: The cost of 
diabetic-related complications is considerable even in the ﬁ rst year of newly diagnosed 
type 2 patients.
PODIUM SESSION III: HEALTH TECHNOLOGY ASSESSMENT
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ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT
DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
Bending MW1, Kruger J1, Hutton J1, McGrath C2
1University of York, York, North Yorkshire, UK, 2Pﬁ zer Inc, Surrey, UK
OBJECTIVES: Health technology assessment is used to inform reimbursement deci-
sions for pharmaceuticals globally. The national HTA agencies of the developed world 
have broadly similar methods and use common factors when evaluating technologies 
but sometimes come to different decisions. The aim of this study was to investigate 
the context level and product-related level factors affecting reimbursement decisions
between countries. METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and cardiovascular medicines. 
Where insufﬁ cient information was published, or reports were not available in English,
decisions were excluded. The analysis was conducted using multinomial logistic regres-
sions and the independent variable included three types of decision: recommended,
recommended for restricted use and not recommended. RESULTS: Detailed informa-
tion was obtained on 194 decisions from Australia, Belgium, Canada, UK, France,
and Sweden. The pooled analysis showed that 27% of medicines were recommended,
41% were recommended for restricted use and 32% were not recommended. The
results demonstrated that several factors were important in producing the different 
types of decision. These included the number of RCTs, publication date, sensitivity
analysis, budget impact, type of medicine and public interest. A sub-analysis for deci-
sions in England showed that the cost per QALY value was statistically signiﬁ cant.
CONCLUSIONS: The results may in part be explained by the different approaches
between countries to conducting economic analysis, differences in cost-effectiveness 
thresholds and variation in the weight given to economic evidence. Further variation
may be explained by factors relating to the country context such as the norms, culture
and policy objectives which inﬂ uence the methods and importance of different product 
level factors included in the HTA. The next stage of the research will investigate these 
factors directly.
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HEALTH TECHNOLOGY ASSESSMENT – A COMPREHENSIVE
FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN
ONTARIO
Johnson A1, Sikich N2, Evans G1, Evans W3, Giacomini M4, Glendining M5, Krahn MD6, 
Levin L7, Oh PI8, Perera C2
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Toronto, ON, Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada, 4McMaster 
University, Hamilton, ON, Canada, 5Hamilton Health Sciences, Hamilton, ON, Canada, 
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OBJECTIVES: This work describes the development of a framework for health tech-
nology decisions for Ontario Health Technology Advisory Committee (OHTAC) in
Ontario, Canada. The focus of the work is on the development of an explicit frame-
work for the recommendation of adoption of new health technologies. METHODS:
OHTAC convened a “Decision Determinants Sub-Committee” in January 2007 which 
undertook a systematic literature review and conducted key informant interviews to 
develop an explicit decision making framework. The purpose of the literature review 
and key informant interviews was to examine methods and models relevant in our 
setting. The main research questions were the following: a) what criteria are used to
make health technology recommendations?; b) what methods are used to evaluate
health technologies using these criteria (e.g., assigned weights, ranking, rating)?; and 
c) what methodology is used to synthesize these criteria (e.g., process/rules/frame-
works). RESULTS: Given the literature review and views provided by key informants,
the “Decision Determinants Sub-Committee” offered recommendations about decision
criteria, and the process by which decisions are made. Decision criteria include 1)
overall clinical beneﬁ t; 2) consistency with societal and ethical values; 3) value 
for money; and 4) feasibility of adoption into the health system. The sub-committee 
drew on several key ideas: evidence based medicine to reﬂ ect the primacy of scientiﬁ c
evidence, cost-effectiveness analysis to reﬂ ect the importance of using society’s 
resources wisely, and “Accountability for Reasonableness” to describe the elements 
of a fair decision-making process, and a deliberative process to describe how 
separate attributes of health technology ought to be evaluated and weighed. CON-
CLUSIONS: This methodology is currently being pilot tested in a live environment: 
OHTAC. It will be evaluated and revised according to its feasibility, acceptability and
perceived usefulness. The transparency of the process should enable one to have a
clear understanding of how OHTAC arrives at its recommendations regarding speciﬁ c 
technologies.
HT3
A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET
CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR
DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY
ASSESSMENT REQUIREMENTS
Mallick R1, Sillup GP2
1Risk Sharing Solutions, Collegeville, PA, USA, 2St. Joseph’s University, Philadelphia, PA, USA
OBJECTIVE: Advancement of innovative drugs into commercial development is
increasingly subjected to rigorous internal reviews by manufacturers for minimal 
